Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
I don’t understand your point at all.
I haven’t yet taken up my open offer of 1/37. But I fully intend to take up the full amount. I think many others are in the same position.
We won’t know it is under-subscribed until after the deadline to accept. Until then, all we know is that some people haven’t yet clicked the accept button.
“There is a distinct sense of urgency, paired with a clear need for safety, in the race to find a treatment for the most debilitating and deadly consequences of COVID-19,” said Graciela Racaro, Senior Vice President and Global Head of Operations, Parexel Biotech. “Working with Synairgen, we are able to share our global reach, deep therapeutic expertise and innovative approaches to support a pivotal study of their novel, inhaled therapy.”
“In the past, we’ve always run our own clinical trials, working with hospitals and research centers,” said Richard Marsden, Chief Executive Officer for Synairgen. (Read more…) “In the case of the SG018 trial, however, there is a clear need to find a global partner to ensure a smooth, fast, and successful trial. We look forward to working with Parexel Biotech as we progress this potential breakthrough therapy for COVID-19 patients.”